Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
作者信息
Hoiland Ryan L, Stukas Sophie, Cooper Jennifer, Thiara Sonny, Chen Luke Y C, Biggs Catherine M, Hay Kevin, Lee Agnes Y Y, Shojania Kamran, Abdulla Alym, Wellington Cheryl L, Sekhon Mypinder S
机构信息
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
Centre for Heart, Lung, and Vascular Health, School of Health and Exercise Sciences, University of British Columbia - Okanagan, Kelowna, BC, Canada.
出版信息
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
Abstract
摘要
相似文献
1
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
2
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.白细胞介素-6阻断治疗用于一名慢性髓性白血病控制不佳患者的新型冠状病毒肺炎相关细胞因子释放综合征
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
3
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
4
Cytokine Storm Drugs Move from CAR T to COVID-19.细胞因子风暴药物从 CAR-T 疗法转移到 COVID-19。
Cancer Discov. 2020 Jul;10(7):OF8. doi: 10.1158/2159-8290.CD-ND2020-008. Epub 2020 May 5.
5
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.视神经脊髓炎谱系障碍患者在新冠疫情期间的免疫抑制：一项新挑战。
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.
6
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
7
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.白细胞介素-6 在 COVID-19 患者肺部并发症中的作用：治疗意义。
In Vivo. 2020 Jun;34(3 Suppl):1589-1592. doi: 10.21873/invivo.11947.
8
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.2019年冠状病毒病的免疫学特征：T细胞功能耗竭与细胞因子风暴
J Clin Immunol. 2020 Oct;40(7):974-976. doi: 10.1007/s10875-020-00824-4. Epub 2020 Jul 10.
9
Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.在用托珠单抗治疗的肾移植受者中，细胞因子释放综合征迅速缓解，重症 COVID-19 临床病程良好。
Kidney Int. 2020 Aug;98(2):508-509. doi: 10.1016/j.kint.2020.05.022. Epub 2020 Jun 4.
10
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
引用本文的文献
1
Network Pharmacology and Experiment Verification-Based Strategy for Exploring the Mechanisms of Shuqing Granule in the Treatment of COVID-19.基于网络药理学和实验验证的疏清颗粒治疗新型冠状病毒肺炎作用机制探究策略
Pharmaceuticals (Basel). 2025 Aug 18;18(8):1216. doi: 10.3390/ph18081216.
2
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.ABO血型与新冠病毒病严重程度：与危重症患者内皮细胞和脂肪细胞激活的关联
PLoS One. 2025 Apr 2;20(4):e0320251. doi: 10.1371/journal.pone.0320251. eCollection 2025.
3
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.中国奥密克戎流行期间，重症和危重症奥密克戎感染患者的免疫和炎症特征。
BMC Infect Dis. 2024 Aug 9;24(1):809. doi: 10.1186/s12879-024-09652-y.
4
A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.嵌合抗原受体T细胞疗法期间细胞因子释放综合征的计算模型。
Adv Ther (Weinh). 2022 Oct;5(10). doi: 10.1002/adtp.202200130. Epub 2022 Aug 4.
5
Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer.基于理性设计的肽适体增强 SARS-CoV-2 诱导炎症的无标记纳米等离子体细胞因子检测
ACS Appl Mater Interfaces. 2022 Nov 2;14(43):48464-48475. doi: 10.1021/acsami.2c14748. Epub 2022 Oct 25.
6
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.与基于体重给药相比，在新冠肺炎危重症患者中降低托珠单抗固定剂量至400mg静脉注射：一项前后队列研究。
Lancet Reg Health Am. 2022 Jul;11:100228. doi: 10.1016/j.lana.2022.100228. Epub 2022 Mar 23.
7
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.药物免疫调节干预以避免 SARS-CoV-2 感染中细胞因子风暴相关的疾病严重程度。
Inflammopharmacology. 2022 Feb;30(1):23-49. doi: 10.1007/s10787-021-00903-x. Epub 2022 Jan 20.
8
Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.Mini-Factor H 调节免疫细胞培养物（PBMC）模型中补体依赖性的 IL-6 和 IL-10 释放：针对细胞因子风暴的潜在益处。
Front Immunol. 2021 Apr 28;12:642860. doi: 10.3389/fimmu.2021.642860. eCollection 2021.
9
Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?新冠病毒病分阶段治疗：间充质干细胞疗法还有空间吗？
Regen Med. 2021 May;16(5):477-494. doi: 10.2217/rme-2020-0189. Epub 2021 May 14.
10
Absence of "Cytokine Storm" in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.住院的COVID-19患者中不存在“细胞因子风暴”：一项回顾性队列研究。
Infect Dis Rep. 2021 Apr 19;13(2):377-387. doi: 10.3390/idr13020036.
本文引用的文献
1
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.应对 COVID-19 风暴：血液细胞因子综合征的经验教训。
Blood Rev. 2021 Jan;45:100707. doi: 10.1016/j.blre.2020.100707. Epub 2020 May 15.
2
Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.新型冠状病毒肺炎合并急性呼吸窘迫综合征患者体液中的细胞因子水平：病例报告
Ann Intern Med. 2020 Sep 15;173(6):499-501. doi: 10.7326/L20-0354. Epub 2020 May 12.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.重症监护病房中应对新型冠状病毒肺炎：血管功能障碍、血栓形成与炎症失调
Intensive Care Med. 2020 Jun;46(6):1105-1108. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.
5
Elevated interleukin-6 and severe COVID-19: A meta-analysis.白细胞介素-6升高与重症新型冠状病毒肺炎：一项荟萃分析。
J Med Virol. 2020 Nov;92(11):2283-2285. doi: 10.1002/jmv.25948. Epub 2020 Jun 2.
6
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
7
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
8
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.中国武汉 69 例 2019 年冠状病毒病患者的临床特征。
Clin Infect Dis. 2020 Jul 28;71(15):769-777. doi: 10.1093/cid/ciaa272.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
Zotero 插件